ERBB2 and breast cancer: Trastuzumab (Herceptin®), a humanized monoclonal antibody against the extracellular domain of HER2, has been widely used in HER2 positive breast cancer (BC) and GC in combination with chemotherapy in clinical treatment [8–11].